INCYTE CORP Q3 FY2026 earnings call

• Strategic Focus: The company is executing a two-part strategy: scaling the core business beyond Jackify to fund R&D and navigating the 29 transition, while advancing a late-stage pipeline to drive long-term growth.
• Pipeline Progress: Several compounds are in Phase III development, including a mutant Cal-R antibody for MPNs, a protein S modulator for von Willebrand's disease, a G12D inhibitor for pancreatic cancer, a TGF-beta by PD-1 bispecific antibody for colorectal cancer, a CDK2 inhibitor for ovarian cancer, and a JAK inhibitor under regulatory review for HS.
• Regulatory Milestones: Opsalora was approved and launched for moderate AD in the EU. NDA reviews for Monjuvi (frontline DLBCL) and Bacitinib (moderate to severe HS) are well underway.
• Product Launches & Access: Jackify XR uptake is increasing, with formulary coverage expected to exceed 80% by year-end. The company aims to retain 10% to 30% of the Jackify business by 2029 through XR adoption.
• Growth Outlook: The non-Jackify core business is on track to grow to $3 to $4 billion by 2030, supported by broad-based growth across indications and geographies.

• Jackify Franchise: Net sales of $827 million, up 4% year-over-year. This reflects strong underlying demand (up 12%) offset by pricing dynamics including the CMS generous model impact. Jackify XR contributed $15 million, with its share rising to approximately 3%.
• Core Business (Ex-Jackify): Net sales of $490 million, representing a 30% increase versus the prior year. Growth was driven by key brands including Opsalora, Nick Timbo, Zioniz, and Monjuvi.
• Opsalora: Net sales of $255 million, an increase of 36% over the prior year. U.S. net sales were $208 million, up 45% year-over-year. On a pro forma basis (adjusting for prior year Medicaid settlement), total growth was 21%.

• Jackify XR Target: Management reaffirms the full-year end target of roughly $50 million in XR net sales, driven by increasing uptake and expanding market access.
• Long-term Jackify Retention: The goal remains to retain 10% to 30% of the Jackify business by 2029 via the transition to XR.
• Core Business Projection: The core business excluding Jackify is expected to reach $3 to $4 billion in net sales by 2030.

• Regulatory Review Uncertainty: While NDA reviews for Monjuvi and Bacitinib are underway, final approval outcomes remain subject to regulatory discretion.
• Pricing Dynamics: Revenue growth is influenced by external factors such as the CMS generous model and Medicaid line extension settlements, which may vary.
• Transition Execution: Successfully scaling the core business and transitioning patients from Jackify to XR requires sustained formulary coverage expansion and patient adherence.
• Forward-Looking Statement Risks: Actual results may differ materially from expectations due to various risks and uncertainties detailed in SEC filings.

Q: Can you elaborate on the sustainability of the 30% growth in the core business and whether it is driven more by volume or price? / A: The growth is primarily volume-driven, fueled by strong demand for Opsalora and emerging contributions from Nick Timbo, Zioniz, and Monjuvi. While U.S. pricing dynamics have been favorable due to CMS agreements, the underlying clinical demand across all indications remains robust, suggesting this trend is sustainable as we approach 2030 targets.

Q: What is the current status of the Jackify XR launch, and how does it impact the overall Jackify franchise revenue decline? / A: Jackify XR net sales reached $15 million in Q3, with its share of the franchise increasing to approximately 3%. Formulary coverage is projected to exceed 80% by year-end. Although total Jackify sales grew only 4%, this masks the 12% underlying demand growth, indicating that pricing headwinds are being offset by volume and successful XR penetration.

Q: How confident is management in the late-stage pipeline, particularly regarding the timeline for potential approvals? / A: Management expressed high confidence in the biology behind several Phase III programs, including the G12D inhibitor and TGF-beta by PD-1 bispecific antibody. While specific timelines depend on ongoing trial expansions and regulatory interactions, the breadth of the pipeline provides substantial value creation potential if these compounds deliver against their endpoints.